These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38066025)

  • 1. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study.
    Greeshma LR; Joseph AP; Sivakumar TT; Raghavan Pillai V; Vijayakumar G
    Sci Rep; 2023 Dec; 13(1):21698. PubMed ID: 38066025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma.
    Kujan O; Agag M; Smaga M; Vaishnaw Y; Idrees M; Shearston K; Farah CS
    Pathology; 2022 Jun; 54(4):409-416. PubMed ID: 34872754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
    Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H
    J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.
    Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
    APMIS; 2018 Sep; 126(9):732-738. PubMed ID: 30160018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of PD-1/PD-L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma.
    Xu SB; Wang MY; Shi XZ; Wang Q; Yu M; Zhang W; Xu XH; Liu LK
    Oral Dis; 2023 Nov; 29(8):3268-3277. PubMed ID: 35921211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity.
    Saeed S; Rauf F; Iqbal F; Khan AS; Khan AH; Alamgeer R
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4039-4045. PubMed ID: 36579984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
    Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
    Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
    Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
    Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions.
    Yagyuu T; Hatakeyama K; Imada M; Kurihara M; Matsusue Y; Yamamoto K; Obayashi C; Kirita T
    Oral Oncol; 2017 May; 68():36-43. PubMed ID: 28438290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study.
    Dave K; Ali A; Magalhaes M
    Sci Rep; 2020 Jun; 10(1):9705. PubMed ID: 32546692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of smoking status and programmed death-ligand 1 expression on the microenvironment and malignant transformation of oral leukoplakia: A retrospective cohort study.
    Yagyuu T; Funayama N; Imada M; Kirita T
    PLoS One; 2021; 16(4):e0250359. PubMed ID: 33861793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value and clinicopathological status of PD-L1 expression and CD8+ TILs in oral squamous cell cancer patients with or without traditional risk factors.
    Soopanit T; Laokulrath N; Chayopasakul V; Pongsapich W
    Head Neck; 2023 Apr; 45(4):1017-1025. PubMed ID: 36811208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
    Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
    J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
    Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.
    Nocini R; Vianini M; Girolami I; Calabrese L; Scarpa A; Martini M; Morbini P; Marletta S; Brunelli M; Molteni G; Parwani A; Pantanowitz L; Eccher A
    Clin Exp Dent Res; 2022 Jun; 8(3):690-698. PubMed ID: 35593124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
    Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
    Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.